Literature DB >> 2159090

Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle.

D J Richel1, L P Colly, M W Arentsen-Honders, C W Starrenburg, R Willemze.   

Abstract

In this study we investigated the Ara-CTP-forming capacity of leukemic cells in different phases of the cell cycle. Cells from two leukemic cell lines and leukemic bone marrow cells from patients and rats (BNML model) with acute myelocytic leukemia were separated according to cell cycle phase by means of an albumin density gradient in a specially designed sedimentation chamber. We found that the activity of CdR kinase and Cyt deaminase is much less influenced by cell-cycle phase progression than TdR kinase activity. For the leukemic cell lines HL-60 and BNML-CL/O CdR kinase activity is even independent of cell-cycle phase. In addition, Ara-CTP formation is not restricted to cells in S-phase. Cell cycle phase-independent Ara-CTP formation creates a situation in which cells which are not in S-phase during exposure to Ara-C might undergo the cytotoxic effects of Ara-C as soon as they enter S-phase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159090     DOI: 10.1016/0145-2126(90)90164-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Enhancement of Ca(2+)-dependent endonuclease activity in L1210 cells during apoptosis induced by 1-beta-D-arabinofuranosylcytosine: possible involvement of activating factor(s).

Authors:  R Takauji; A Yoshida; H Iwasaki; K Tohyama; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1995-07

Review 3.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.

Authors:  An R Van Rompay; Magnus Johansson; Anna Karlsson
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.